Unbiased, cited ebooks on peptide therapy — organized by what you're trying to achieve, not what anyone is trying to sell you. Six canonical guide pages live here; the catalog also includes the legacy GLP-1 guide. Each one grade-rates the underlying evidence and calls out what the research does and doesn't show.
Mechanism walk-through, evidence map (NO / VEGFR2 / tendon fibroblast / EGF / gastric mucosa), Sikiric-lab COI disclosure, dosing reality vs. Lee & Burgess 2025 IV, FDA Category 2 / WADA S0 status, and honest verdict.
G-actin sequestration / cell-migration / angiogenesis mechanism walk-through, Goldstein rodent vs. zero human RCT evidence map, FDA / WADA status, risks, and honest verdict on the Thymosin Beta-4 grouping.
Mechanism walk-through, topical-vs-injectable evidence map (Lorentic 2012 / Draelos 2006 / Pickart 1973), cosmetic vs. injectable regulatory framing, honest verdict split by delivery method.
Selective ghrelin-receptor GHRP: mechanism, the Raun 1998 healthy-volunteer GH-pulse data anchor, what the GH-pulse data actually shows versus body-composition / recovery-sleep claims, dosing matrix, and WADA S2 / FDA compounding status.
Synthetic GHRH 1–29 analog: upstream GHRH-receptor amplification of endogenous GH pulsatility, the Reutens 1996 / Walker 1994 narrow-window adult diagnostic-stim evidence anchor, the 2008 US-market withdrawal context, and WADA S2 GH-Releasing Factors status.
Long-acting GHRH analog (with or without DAC): same upstream GHRH-receptor mechanism as Sermorelin with an extended pharmacokinetic window, evidence map (Reutens 1996 / Walker 1994 GH-stim context — zero body-composition / anti-aging / sleep RCTs), dosing matrix, and WADA S2 / FDA compounding status.
Three ways to read the guides. Pick a single guide, get all seven, or add the weekly regulatory-evidence digest.